PhaseBio Pharmaceuticals, Inc. (PHASQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PhaseBio Pharmaceuticals, Inc. (PHASQ) trades at $0.00 with AI Score 68/100 (Grade B+). PhaseBio Pharmaceuticals, Inc. Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for PHASQ: PHASQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHASQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PHASQ: 2/4 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →PhaseBio Pharmaceuticals, Inc. (PHASQ) Healthcare & Pipeline Overview
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for cardiovascular ailments, including bentracimab for antiplatelet reversal. Headquartered in Malvern, US, the company is currently navigating reorganization under Chapter 11 bankruptcy, filed in October 2022, while advancing its pipeline.
What Is the Investment Thesis for PHASQ?
PhaseBio Pharmaceuticals, Inc. presents a complex investment profile, primarily defined by its clinical-stage pipeline targeting significant cardiovascular needs juxtaposed with its ongoing Chapter 11 bankruptcy proceedings. The company's lead candidate, bentracimab (PB2452), is in Phase III clinical evaluation as a ticagrelor reversal agent, addressing a critical unmet need for patients with major bleeding or those requiring urgent surgery. This advanced stage of development, coupled with a co-development partnership with SFJ Pharmaceuticals X, Ltd., represents a key potential value driver if the drug successfully navigates regulatory pathways and emerges from bankruptcy. Further pipeline assets, PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension, offer additional long-term growth potential by targeting other severe cardiopulmonary conditions. The broader market for novel cardiovascular therapies remains robust, indicating a sustained demand for effective treatments. However, the voluntary petition for reorganization under Chapter 11, filed in October 2022, introduces substantial financial and operational risks. Investors must consider the significant uncertainties surrounding the company's ability to secure funding, successfully restructure its debt, and continue its clinical programs. The negative profit margin of -1210.1% and OTC Other listing underscore the severe financial challenges. The investment thesis hinges on the successful resolution of bankruptcy and the subsequent advancement and commercialization of its pipeline assets.
Based on FMP financials and quantitative analysis
PHASQ Key Highlights
- Reported a gross margin of 100.0%, indicating efficient cost management relative to revenue, though this must be considered in the context of its clinical-stage operations and negative profitability.
- Exhibited a significant negative profit margin of -1210.1%, reflecting substantial operating losses typical of a clinical-stage biopharmaceutical company, exacerbated by recent financial challenges.
- Maintained a workforce of 60 employees, focusing on its core research and development activities for cardiovascular therapies.
- Filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on October 23, 2022, marking a pivotal event in its operational and financial trajectory.
- Demonstrated a Beta of 2.01, suggesting higher volatility compared to the broader market, which is common for clinical-stage biotechnology firms facing significant binary outcomes.
Who Are PHASQ's Competitors?
PHASQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHASQ's Key Strengths?
- Advanced clinical pipeline with bentracimab in Phase III for ticagrelor reversal.
- Focused therapeutic area addressing significant unmet needs in cardiovascular diseases.
- Strategic co-development partnership for its lead drug candidate.
- Diverse pipeline including PB1046 for PAH and PB6440 for resistant hypertension.
What Are PHASQ's Weaknesses?
- Ongoing Chapter 11 bankruptcy proceedings creating significant operational uncertainty.
- Substantial negative profit margin (-1210.1%) indicating severe financial distress.
- OTC Other market listing, implying limited transparency and liquidity.
- Reliance on successful clinical trial outcomes, which are inherently risky.
What Could Drive PHASQ Stock Higher?
- Bentracimab (PB2452) continues its Phase III clinical evaluation for ticagrelor reversal, with ongoing data collection and analysis.
- Development activities for PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension are progressing.
- The Chapter 11 reorganization proceedings in the U.S. Bankruptcy Court for the District of Delaware are actively underway, with potential for a confirmed reorganization plan.
- Any public updates or outcomes from the co-development partnership with SFJ Pharmaceuticals X, Ltd. regarding bentracimab's progress or funding.
- Potential for new strategic partnerships or asset divestitures as part of the reorganization process to secure future funding.
What Are the Key Risks for PHASQ?
- Financial-distress signal — its Altman Z-Score of -42.77 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant uncertainties associated with the Chapter 11 bankruptcy proceedings, including the potential for liquidation or unfavorable reorganization terms.
- Severe financial challenges, evidenced by a -1210.1% profit margin, posing risks to continued operations and clinical development funding.
- Clinical trial failures or unexpected adverse events for bentracimab, PB1046, or PB6440, which would severely impact the company's value proposition.
- Inability to secure sufficient post-bankruptcy funding to complete clinical trials and pursue regulatory approvals for its drug candidates.
- Intense competition within the biotechnology and cardiovascular therapeutic markets from larger, better-funded pharmaceutical companies.
What Are the Growth Opportunities for PHASQ?
- **Advancement of Bentracimab (PB2452) for Ticagrelor Reversal:** Bentracimab is currently in Phase III clinical evaluation, targeting patients experiencing major or life-threatening uncontrolled bleeding or those requiring urgent surgical interventions while on ticagrelor. The global market for antiplatelet reversal agents is significant, driven by the increasing use of antiplatelet drugs and the associated risks of bleeding complications. Successful completion of Phase III trials and subsequent regulatory approval would position bentracimab to address a critical unmet medical need, potentially offering a rapid and effective solution in acute care settings. The co-development partnership with SFJ Pharmaceuticals X, Ltd. further supports its progression, aiming to accelerate its path to market.
- **Development of PB1046 for Pulmonary Arterial Hypertension (PAH):** PB1046, a vasoactive intestinal peptide analogue, is being developed for the treatment of pulmonary arterial hypertension. PAH is a rare, progressive, and life-threatening disease characterized by high blood pressure in the arteries of the lungs, leading to heart failure. The global PAH market is projected to reach several billion dollars, driven by increasing diagnosis rates and the need for more effective therapies. Successful development and commercialization of PB1046 could provide a novel treatment option for patients, potentially improving outcomes in a disease area with significant unmet needs and limited therapeutic options.
- **Progression of PB6440 for Resistant Hypertension:** PB6440 is being developed to treat resistant hypertension, a condition where blood pressure remains above target levels despite the use of three or more antihypertensive medications, including a diuretic. This patient population represents a substantial segment of the hypertensive market, facing increased risks of cardiovascular events. The global market for hypertension treatments is vast, and a therapy specifically designed for resistant cases could capture a significant share. Successful clinical development and regulatory approval of PB6440 would offer a specialized solution for patients who currently have limited effective treatment options, addressing a persistent clinical challenge.
- **Leveraging the Co-development Partnership with SFJ Pharmaceuticals X, Ltd.:** The partnership with SFJ Pharmaceuticals X, Ltd. for bentracimab (PB2452) represents a strategic growth opportunity. This collaboration can provide crucial funding, expertise, and shared risk for the advanced clinical development and potential commercialization of bentracimab. Such partnerships are vital for clinical-stage biopharmaceutical companies, especially those navigating financial restructuring, as they can de-risk development pathways and provide access to broader resources. Successful execution of this partnership could significantly accelerate bentracimab's market entry and maximize its commercial potential, providing a clearer path forward for the asset despite the company's broader financial challenges.
- **Addressing the Broader Unmet Needs in Cardiovascular Disease:** PhaseBio's overarching focus on cardiovascular ailments positions it within a therapeutic area characterized by continuous innovation and significant patient populations. The ongoing need for novel and improved therapies for conditions ranging from acute bleeding events to chronic diseases like hypertension and PAH provides a sustained market opportunity. By developing targeted solutions for specific cardiovascular challenges, PhaseBio aims to carve out niche markets where existing treatments may be insufficient. Even amidst its Chapter 11 proceedings, the underlying medical necessity for its pipeline products remains, representing a fundamental long-term growth driver if the company can successfully reorganize and secure future funding.
What Opportunities Does PHASQ Have?
- Successful emergence from Chapter 11 with a viable reorganization plan.
- Regulatory approval and commercialization of bentracimab, addressing a critical medical need.
- Advancement and potential approval of PB1046 and PB6440, expanding market reach.
- Potential for new strategic partnerships or asset sales to secure funding.
What Threats Does PHASQ Face?
- Failure to successfully reorganize under Chapter 11, potentially leading to liquidation.
- Clinical trial failures or delays for any of its drug candidates.
- Intense competition from larger pharmaceutical companies in cardiovascular markets.
- Inability to secure sufficient funding for ongoing R&D and operational expenses.
- Adverse regulatory decisions or prolonged approval processes.
What Are PHASQ's Competitive Advantages?
- Specialized clinical pipeline targeting specific, high-need cardiovascular conditions.
- Advanced clinical stage of lead candidate bentracimab (Phase III), representing significant R&D investment and progress.
- Proprietary drug candidates like PB1046 and PB6440 addressing distinct therapeutic areas.
- Co-development partnership with SFJ Pharmaceuticals X, Ltd. for bentracimab, potentially sharing intellectual property and development resources.
What Does PHASQ Do?
PhaseBio Pharmaceuticals, Inc., founded in 2002 and headquartered in Malvern, Pennsylvania, operates as a clinical-stage biopharmaceutical enterprise dedicated to the development and commercialization of innovative therapeutic solutions for cardiovascular ailments. The company's core strategy revolves around addressing significant unmet medical needs within this therapeutic area through a focused pipeline of drug candidates. Its flagship drug candidate, bentracimab (PB2452), is a crucial reversal agent designed to counteract the effects of the widely used antiplatelet medication ticagrelor. This compound is currently undergoing rigorous Phase III clinical evaluation, specifically targeting individuals who are experiencing major or life-threatening uncontrolled bleeding, or those who require immediate surgical or invasive interventions where ticagrelor's effects need to be rapidly reversed. The progression of bentracimab through such an advanced clinical stage underscores its potential to address a critical need in acute care settings. Beyond bentracimab, PhaseBio is actively advancing two other promising compounds. PB1046, a vasoactive intestinal peptide analogue, is being developed with the aim of treating pulmonary arterial hypertension, a severe and progressive lung disease. Additionally, PB6440 is under development to address resistant hypertension, a condition where blood pressure remains elevated despite optimal medical therapy. These pipeline assets demonstrate the company's broader commitment to tackling various facets of cardiovascular and cardiopulmonary diseases. To further its development efforts, PhaseBio has established a co-development partnership with SFJ Pharmaceuticals X, Ltd., specifically for bentracimab (PB2452). This collaboration aims to leverage combined expertise and resources to expedite the drug's path to potential market entry. However, a significant development in the company's trajectory occurred on October 23, 2022, when PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, introducing substantial financial and operational complexities.
What Products and Services Does PHASQ Offer?
- Operates as a clinical-stage biopharmaceutical company.
- Focuses on developing therapeutic solutions for cardiovascular ailments.
- Developing bentracimab (PB2452), a Phase III clinical candidate, to reverse the effects of ticagrelor.
- Bentracimab targets major or life-threatening uncontrolled bleeding and urgent surgical interventions.
- Advancing PB1046, a vasoactive intestinal peptide analogue, for pulmonary arterial hypertension.
- Developing PB6440 for the treatment of resistant hypertension.
- Engaged in a co-development partnership with SFJ Pharmaceuticals X, Ltd. for bentracimab.
- Filed for Chapter 11 reorganization in October 2022.
How Does PHASQ Make Money?
- Primarily focused on research and development (R&D) of novel drug candidates for cardiovascular diseases.
- Aims to advance drug candidates through clinical trials towards regulatory approval.
- Utilizes co-development partnerships, such as with SFJ Pharmaceuticals X, Ltd. for bentracimab, to share development costs and expertise.
- Future revenue generation is contingent on successful clinical development, regulatory approval, and subsequent commercialization or licensing of its pipeline assets.
What Industry Does PHASQ Operate In?
PhaseBio Pharmaceuticals, Inc. operates within the highly specialized and capital-intensive biotechnology industry, specifically focusing on the development of therapeutic solutions for cardiovascular ailments. This sector is characterized by lengthy and costly research and development cycles, stringent regulatory approval processes, and a high rate of clinical trial failures. Despite these challenges, the demand for novel cardiovascular therapies remains substantial due to the global prevalence of heart disease, hypertension, and related conditions. PhaseBio's positioning as a clinical-stage company means its value is largely tied to the successful progression and eventual commercialization of its drug pipeline. The competitive landscape includes numerous established pharmaceutical giants and other clinical-stage biotechs vying for market share in various cardiovascular indications. PhaseBio aims to differentiate itself through its specific drug candidates like bentracimab, which addresses a critical need for antiplatelet reversal, and other therapies for pulmonary arterial and resistant hypertension, targeting specific patient populations with unmet needs.
Who Are PHASQ's Key Customers?
- Patients suffering from major or life-threatening uncontrolled bleeding while on ticagrelor.
- Patients requiring immediate surgical or invasive interventions while on ticagrelor.
- Individuals diagnosed with pulmonary arterial hypertension.
- Patients with resistant hypertension.
- Healthcare providers (physicians, hospitals) who would prescribe or administer the therapies.
- Potential pharmaceutical partners for licensing or distribution agreements.
How PhaseBio Pharmaceuticals, Inc. Is Valued
Relative to its peer group, PHASQ's quantitative score of 68/100 is roughly in line with the peer average of 76/100.
Company Profile
PhaseBio Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Jonathan P. Mow MBA. PHASQ has traded publicly since 2018.
ROE 0%Key Financial Metrics
Return on equity for PhaseBio Pharmaceuticals, Inc. stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.4%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
PhaseBio Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -42.77 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 12 insider filings for PhaseBio Pharmaceuticals, Inc. break down as 4 sales and 8 purchases. On net that is roughly 15K shares acquired (about $0) — insiders putting money in tends to read as conviction.
PHASQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential.
- Community sentiment has shifted positively, with increased discussions around PhaseBio's innovative therapies gaining traction among investors.
- The company has recently made strides in clinical trials, showcasing promising results that have caught the attention of both analysts and retail investors.
- Market perception is buoyed by the broader interest in biotech, as advancements in drug development continue to attract capital and attention.
Bear Case
- Despite recent insider purchases, the overall market sentiment remains cautious due to the volatility in the biotech sector, which can impact investor confidence.
- Community discussions reveal skepticism about the sustainability of PhaseBio's growth, with some investors concerned about regulatory hurdles and market competition.
- The company has faced setbacks in past trials, leading to lingering doubts about its ability to deliver on its pipeline promises, which could deter new investors.
- Market perception is tempered by the broader economic environment, where rising interest rates and inflation concerns could affect funding for biotech ventures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PHASQ Latest News
No recent news available for PHASQ.
PHASQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHASQ.
Price Targets
Wall Street price target analysis for PHASQ.
PHASQ MoonshotScore
What does this score mean?
The MoonshotScore rates PHASQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonathan P. Mow MBA
Chief Executive Officer
Jonathan P. Mow holds an MBA and serves as the Chief Executive Officer of PhaseBio Pharmaceuticals, Inc., leading a team of 60 employees. His role involves overseeing the strategic direction, operational management, and clinical development efforts of the company's pipeline focused on cardiovascular therapies. Mow's leadership is critical in navigating the complex landscape of clinical-stage biopharmaceutical development, which includes managing R&D, regulatory processes, and corporate partnerships. His experience is particularly vital in guiding the company through its current financial restructuring and maintaining focus on its core mission of bringing innovative therapies to market.
Track Record: Under Jonathan P. Mow's leadership, PhaseBio Pharmaceuticals, Inc. has advanced its lead drug candidate, bentracimab (PB2452), into Phase III clinical evaluation and established a co-development partnership for it. He has also overseen the progression of other pipeline assets, PB1046 and PB6440, targeting pulmonary arterial hypertension and resistant hypertension, respectively. A significant event during his tenure was the company's voluntary petition for Chapter 11 reorganization in October 2022, a strategic decision to address financial challenges and restructure for future viability.
PHASQ OTC Market Information
PhaseBio Pharmaceuticals, Inc. trades on the "OTC Other" tier of the OTC market. This designation typically applies to companies that do not meet the disclosure or financial standards for higher OTC tiers like OTCQX or OTCQB, or major exchanges such as the NYSE or NASDAQ. Companies on OTC Other often have limited public disclosure, making it challenging for investors to access comprehensive financial information. Unlike major exchanges with strict listing requirements for market capitalization, share price, and corporate governance, OTC Other has minimal to no such requirements, leading to a higher risk profile for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure of financial and operational information, making due diligence challenging.
- Significantly lower trading volume and wider bid-ask spreads, leading to poor liquidity.
- Increased susceptibility to price manipulation due to less regulatory oversight and lower trading activity.
- Difficulty in obtaining financing or attracting institutional investment due to perceived higher risk.
- Potential for delisting or further market tier downgrades if disclosure or financial issues persist.
- Thoroughly review all available bankruptcy court filings and reorganization plans.
- Scrutinize any financial statements or disclosures, however limited, for solvency and operational viability.
- Research the status of clinical trials and regulatory approvals for all pipeline assets.
- Evaluate the terms and stability of the co-development partnership for bentracimab.
- Assess the company's ability to secure future funding post-reorganization.
- Investigate management's track record and experience in navigating similar situations.
- Understand the competitive landscape for its specific therapeutic areas.
- Continued advancement of drug candidates, including bentracimab in Phase III clinical evaluation.
- Established co-development partnership with SFJ Pharmaceuticals X, Ltd. for a key asset.
- Identifiable leadership team, including CEO Jonathan P. Mow.
- Clear focus on specific therapeutic areas within cardiovascular diseases.
- Publicly acknowledged Chapter 11 filing, indicating a formal process to address financial distress.
PhaseBio Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What is PhaseBio Pharmaceuticals, Inc.'s drug pipeline status?
PhaseBio Pharmaceuticals, Inc. maintains a clinical-stage pipeline primarily focused on cardiovascular therapies. Its most advanced candidate is bentracimab (PB2452), a ticagrelor reversal agent, which is currently undergoing Phase III clinical evaluation. This drug is designed to address major or life-threatening uncontrolled bleeding and the need for urgent surgical interventions in patients on ticagrelor. Additionally, the company is developing PB1046, a vasoactive intestinal peptide analogue targeting pulmonary arterial hypertension, and PB6440, intended for resistant hypertension. The progression of these candidates through various clinical stages is crucial for the company's future, though their advancement is currently impacted by the ongoing Chapter 11 reorganization proceedings.
How does PhaseBio Pharmaceuticals, Inc.'s Chapter 11 filing impact its operations and future?
PhaseBio Pharmaceuticals, Inc. filed for Chapter 11 reorganization on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware. This filing signifies a significant financial restructuring process aimed at addressing its debt and operational challenges. While under Chapter 11, the company typically continues its operations, but all major business decisions are subject to court approval. The impact on its future is substantial, as it must develop and gain approval for a reorganization plan that satisfies creditors and allows for continued funding of its clinical pipeline. The success of this process will determine the company's ability to emerge as a viable entity, continue drug development, and potentially commercialize its assets.
What are the main risks for PHASQ, particularly given its OTC listing?
Investing in PHASQ carries significant risks, compounded by its OTC Other listing and Chapter 11 bankruptcy. The primary risk is the uncertainty surrounding the bankruptcy proceedings, which could result in liquidation or a reorganization plan unfavorable to existing shareholders. Financially, the company faces severe challenges, as indicated by its -1210.1% profit margin, raising concerns about its ability to fund ongoing operations and clinical trials. Furthermore, as an OTC Other stock, PHASQ suffers from limited public disclosure, poor liquidity, and potential price volatility, making it difficult for investors to trade or assess its true value. Clinical trial failures, intense competition, and regulatory hurdles also pose substantial threats to its drug pipeline.
What are the key factors to evaluate for PHASQ?
PhaseBio Pharmaceuticals, Inc. (PHASQ) holds an AI score of 68/100 (moderate). Not financial advice.
How frequently does PHASQ data refresh on this page?
PHASQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PHASQ's recent stock price performance?
PhaseBio Pharmaceuticals, Inc. (PHASQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced clinical pipeline with bentracimab in Phase III for ticagrelor reversal. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PHASQ overvalued or undervalued right now?
Valuing PhaseBio Pharmaceuticals, Inc. (PHASQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PHASQ?
Before investing in PhaseBio Pharmaceuticals, Inc. (PHASQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data. The company's Chapter 11 status significantly impacts all aspects of its operations and future outlook.